Zealand Pharma A/S (0NZU)
London Exchange · UK · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 227.05 |
|---|---|
| 52-week range | 221.70 – 531.60 |
| Return, 1 month / 3 months | −18.2% / −23.5% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 72.4% |
| Worst drawdown (1 year) | -57.7% |
| Average daily value traded | 7.30M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Zealand Pharma is a Danish biotechnology company based in Copenhagen that discovers and develops peptide-based medicines. Its work centres on metabolic and gastrointestinal diseases, and it has developed treatments for severe low blood sugar and for rare conditions affecting the gut. The company also has partnerships with larger pharmaceutical firms to develop and commercialise its drug candidates. Its customers are mainly healthcare providers and patients through partners who market the finished medicines.
Zealand Pharma A/S trades under the code 0NZU on the London Exchange in UK, with its price quoted in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Zealand Pharma A/S (0NZU) trades on the London Exchange in UK. It last closed at DKK 227.05 on 23 October 2026.
Its price-based Market X-Ray is 22 out of 100 (a weak price profile), ranking 3,365 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 12 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -27.6% | ||
| From 52-week high | -56.6% | ||
| Momentum | 13 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -23.5% | ||
| 6-month return | -25.5% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 14 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 72.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -57.7% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 7.30M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.6% |
|---|---|
| 1 month | −18.2% |
| 3 months | −23.5% |
| 6 months | −25.5% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 277.26 / 313.81 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 38.04 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.